JPH0242813B2 - - Google Patents
Info
- Publication number
- JPH0242813B2 JPH0242813B2 JP57021354A JP2135482A JPH0242813B2 JP H0242813 B2 JPH0242813 B2 JP H0242813B2 JP 57021354 A JP57021354 A JP 57021354A JP 2135482 A JP2135482 A JP 2135482A JP H0242813 B2 JPH0242813 B2 JP H0242813B2
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- tumor
- gallium chloride
- diameter
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- UPWPDUACHOATKO-UHFFFAOYSA-K gallium trichloride Chemical compound Cl[Ga](Cl)Cl UPWPDUACHOATKO-UHFFFAOYSA-K 0.000 claims abstract description 33
- 201000011510 cancer Diseases 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 4
- 239000003708 ampul Substances 0.000 claims description 3
- 230000035622 drinking Effects 0.000 claims description 3
- XOYLJNJLGBYDTH-UHFFFAOYSA-M chlorogallium Chemical compound [Ga]Cl XOYLJNJLGBYDTH-UHFFFAOYSA-M 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 206010028980 Neoplasm Diseases 0.000 description 32
- 239000011777 magnesium Substances 0.000 description 21
- 241000282472 Canis lupus familiaris Species 0.000 description 17
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 10
- 229910052749 magnesium Inorganic materials 0.000 description 10
- 238000001356 surgical procedure Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 208000003098 Ganglion Cysts Diseases 0.000 description 4
- 208000008771 Lymphadenopathy Diseases 0.000 description 4
- 208000005400 Synovial Cyst Diseases 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 208000018555 lymphatic system disease Diseases 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 241001620634 Roger Species 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 210000000621 bronchi Anatomy 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010029098 Neoplasm skin Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000013276 bronchoscopy Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 210000003717 douglas' pouch Anatomy 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241000931526 Acer campestre Species 0.000 description 1
- 206010001029 Acute pulmonary oedema Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 102000014702 Haptoglobin Human genes 0.000 description 1
- 108050005077 Haptoglobin Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029488 Nodular melanoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000012321 colectomy Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 210000002455 dental arch Anatomy 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 210000000188 diaphragm Anatomy 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 201000011536 eccrine sweat gland neoplasm Diseases 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000012820 exploratory laparotomy Methods 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 150000002258 gallium Chemical class 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 206010020488 hydrocele Diseases 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- KRCMKUNIILUXPF-UHFFFAOYSA-N methyl 4-hydroxybenzoate;sodium Chemical compound [Na].COC(=O)C1=CC=C(O)C=C1 KRCMKUNIILUXPF-UHFFFAOYSA-N 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 201000010225 mixed cell type cancer Diseases 0.000 description 1
- 208000029638 mixed neoplasm Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000000032 nodular malignant melanoma Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 238000011248 postoperative chemotherapy Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- WXSLOYPZKHFWII-UHFFFAOYSA-N propyl 4-hydroxybenzoate;sodium Chemical compound [Na].CCCOC(=O)C1=CC=C(O)C=C1 WXSLOYPZKHFWII-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004290 sodium methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010230 sodium propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004404 sodium propyl p-hydroxybenzoate Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000000541 transverse mesocolon Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8103355A FR2500303A1 (fr) | 1981-02-20 | 1981-02-20 | Le chlorure de gallium, nouveau medicament anti-cancereux |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57150618A JPS57150618A (en) | 1982-09-17 |
| JPH0242813B2 true JPH0242813B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1990-09-26 |
Family
ID=9255431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57021354A Granted JPS57150618A (en) | 1981-02-20 | 1982-02-15 | Anticancer |
Country Status (8)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3376387D1 (en) * | 1982-10-22 | 1988-06-01 | Sloan Kettering Inst Cancer | The use of gallium salts for the manufacture of pharmaceutical compositions for the treatment of disorders of calcium homeostasis |
| US4686104A (en) * | 1985-04-30 | 1987-08-11 | Sloan-Kettering Institute For Cancer Research | Methods of treating bone disorders |
| US6004951A (en) * | 1989-11-22 | 1999-12-21 | Bernstein; Lawrence Richard | Administration of gallium complexes of 3-hydroxy-4-pyrones to provide physiologically active gallium levels in a mammalian individual |
| US5574027A (en) * | 1989-11-22 | 1996-11-12 | Bernstein; Lawrence R. | Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones |
| US5258376A (en) * | 1989-11-22 | 1993-11-02 | Bernstein Lawrence R | Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones |
| WO1991017751A1 (en) * | 1990-05-24 | 1991-11-28 | Fujisawa, Inc. | Orally administrable gallium compositions and methods of treatment therewith |
| US5747482A (en) * | 1996-07-30 | 1998-05-05 | Bernstein; Lawrence R. | Methods and compositions to inhibit keratinocyte proliferation |
| US20020160055A1 (en) * | 2000-09-18 | 2002-10-31 | Jack Stapleton | Methods for treating human immunodeficiency virus infections with gallium compositions |
| RU2182828C1 (ru) * | 2001-02-23 | 2002-05-27 | Поздняков Владимир Николаевич | Композиция, обладающая антивич и антигерпесной активностью |
| DE10116527C2 (de) * | 2001-04-03 | 2003-05-15 | Faustus Forschungs Cie | Tumorhemmende Galliumverbindungen, deren Verwendung als Arzneimittel sowie ein Arzneimittel, diese enthaltend |
| US7081247B2 (en) * | 2002-05-20 | 2006-07-25 | Nidaria Technology Ltd. | Composition and method for inhibiting polar capsule discharge and protecting a subject from nematocyst sting |
-
1981
- 1981-02-20 FR FR8103355A patent/FR2500303A1/fr active Granted
-
1982
- 1982-02-15 JP JP57021354A patent/JPS57150618A/ja active Granted
- 1982-02-19 EP EP82400298A patent/EP0059148B1/fr not_active Expired
- 1982-02-19 AT AT82400298T patent/ATE13488T1/de not_active IP Right Cessation
- 1982-02-19 DE DE8282400298T patent/DE3263832D1/de not_active Expired
- 1982-02-19 OA OA57625A patent/OA07029A/xx unknown
-
1984
- 1984-05-11 US US06/609,329 patent/US4596710A/en not_active Expired - Fee Related
-
1992
- 1992-06-25 MX MX9203361A patent/MX9203361A/es unknown
Non-Patent Citations (1)
| Title |
|---|
| ARZNEIM-FORSCH=1975 * |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2500303B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1983-12-30 |
| US4596710A (en) | 1986-06-24 |
| OA07029A (fr) | 1983-12-31 |
| EP0059148B1 (fr) | 1985-05-29 |
| DE3263832D1 (en) | 1985-07-04 |
| MX9203361A (es) | 1992-07-01 |
| ATE13488T1 (de) | 1985-06-15 |
| JPS57150618A (en) | 1982-09-17 |
| FR2500303A1 (fr) | 1982-08-27 |
| EP0059148A1 (fr) | 1982-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bennett et al. | Cancer growth, response to treatment and survival time in mice: beneficial effect of the prostaglandin synthesis inhibitor flurbiprofen | |
| ELLIS Jr | Treatment of carcinoma of the esophagus or cardia | |
| CN101528218A (zh) | 治疗粘膜炎的组合物和方法 | |
| JP2714402B2 (ja) | 癌転移抑制剤 | |
| JPH0242813B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| US4384001A (en) | Treatment of tumors with thiazolidine-4-carboxylic acid | |
| JPS6016934A (ja) | 抗腫瘍剤 | |
| CN114159446A (zh) | 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用 | |
| US20090182041A1 (en) | Control of cancer with annonaceous extracts | |
| CN111346081A (zh) | 包含正戊酸、吲哚丙酸和正丁酸钠的药物组合物的新用途 | |
| US20130164382A1 (en) | Ejaculum of animals as medicinal material and uses thereof in medicaments for treatment of diseases such as tumors, depression, etc | |
| EA007685B1 (ru) | Фармацевтическая композиция, содержащая толуолсульфонамид, и способы ее получения и применения | |
| WO1992011247A1 (en) | Anticancer composition and compound | |
| RU2241459C2 (ru) | Способ лечения метастазов колоректального рака в печени | |
| CN115837018A (zh) | 3-羟基巴戟醌在制备抗乳腺癌药物中的应用 | |
| RU2369396C2 (ru) | Фармацевтическая композиция, содержащая оксоплатин, его соли и производные | |
| KR100412424B1 (ko) | 마늘추출물의 전립선암 및 방광암 예방 및 치료제로서의용도 | |
| ES3015109T3 (en) | Dimenhydrinate and calcium pantothenate for preventing and treating muscular disease | |
| Wood et al. | IRRADIATION IN JURY TO THE GASTRO‐INTESTINAL TRACT: CLINICAL FEATURES, MANAGEMENT AND PATHOGENESIS | |
| US5569667A (en) | Treatment of prostate cancer | |
| RU2134589C1 (ru) | Способ лечения первичного рака печени и набор для лечения первичного рака печени | |
| CN116327772B (zh) | SMO抑制剂Sonidegib对管腔型乳腺癌骨转移的靶向治疗方法 | |
| RU2071770C1 (ru) | Способ лечения рака шейки матки и яичников | |
| RU2775008C1 (ru) | Фармацевтическая композиция, обладающая иммуномодулирующей, иммунокорректирующей, иммуносупрессорной, противовирусной, противовоспалительной и онколитической активностями | |
| KR20250099958A (ko) | 종양 혈관 파괴용 약학 조성물 |